{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:38:50Z","timestamp":1793342330993,"version":"4.5.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is the second most frequent subtype of mature T-cell lymphoma (MTCL) in the Western world. It derives from the monoclonal proliferation of T-follicular helper (TFH) cells and is characterized by an exacerbated inflammatory response and immune dysregulation, with predisposition to autoimmunity phenomena and recurrent infections. Its genesis is based on a multistep integrative model, where age-related and initiator mutations involve epigenetic regulatory genes, such as <jats:italic>TET-2<\/jats:italic> and <jats:italic>DNMT3A<\/jats:italic>. Subsequently, driver-mutations, such as <jats:italic>RhoA<\/jats:italic> G17V and <jats:italic>IDH-2<\/jats:italic> R172K\/S promote the expansion of clonal TFH-cells (\u201csecond-hit\u201d), that finally begin to secrete cytokines and chemokines, such as IL-6, IL-21, CXCL-13 and VEGF, modulating a network of complex relationships between TFH-cells and a defective tumor microenvironment (TME), characterized by expansion of follicular dendritic cells (FDC), vessels and EBV-positive immunoblasts. This unique pathogenesis leads to peculiar clinical manifestations, generating the so-called \u201c<jats:italic>immunodysplastic syndrome<\/jats:italic>\u201d, typical of AITL. Its differential diagnosis is broad, involving viral infections, collagenosis and adverse drug reactions, which led many authors to use the term \u201c<jats:italic>many-faced lymphoma<\/jats:italic>\u201d when referring to AITL. Although great advances in its biological knowledge have been obtained in the last two decades, its treatment is still an unmet medical need, with highly reserved clinical outcomes. Outside the setting of clinical trials, AITL patients are still treated with multidrug therapy based on anthracyclines (CHOP-like), followed by up-front consolidation with autologous stem cell transplantation (ASCT). In this setting, the estimated 5-year overall survival (OS) is around 30-40%. New drugs, such as hypomethylating agents (HMAs) and histone deacetylase inhibitors (HDAi), have been used for relapsed\/refractory (R\/R) disease with promising results. Such agents have their use based on a biological rationale, have significant potential to improve the outcomes of patients with AITL and may represent a paradigm shift in the therapeutic approach to this lymphoma in the near future.<\/jats:p>","DOI":"10.3389\/fonc.2023.1177590","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T05:52:27Z","timestamp":1682488347000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu\u00eds Alberto de P\u00e1dua Covas","family":"Lage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert Fabricio","family":"Culler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadiele Oliana","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Aparecida Coelho","family":"da Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2015.03.017","article-title":"Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations","volume":"37","author":"Lage","year":"2015","journal-title":"Rev Bras hematologia e hemoterapia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nri1714","article-title":"Follicular b helper T cells in antibody responses and autoimmunity","volume":"5","author":"Vinuesa","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (Aitl) and follicular helper T (Tfh) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.10.011","article-title":"Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets","volume":"71","author":"Rodr\u00edguez","year":"2009","journal-title":"Crit Rev oncology\/hematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 who classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural Killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181971591","article-title":"Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (Tfh) and may show overlapping features with angioimmunoblastic T-cell lymphomas","volume":"33","author":"Huang","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)90553-4","article-title":"Angio-immunoblastic lymphadenopathy with dysproteinaemia","volume":"1","author":"Frizzera","year":"1974","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/nejm197501022920101","article-title":"Immunoblastic lymphadenopathy. a hyperimmune entity resembling hodgkin's disease","volume":"292","author":"Lukes","year":"1975","journal-title":"New Engl J Med"},{"key":"B16","article-title":"[Nature, prognosis and nomenclature of angioimmunoblastic (Lymphadenopathy (Lymphogranulomatosis X or T-zone lymphoma)]","volume":"104","author":"Lennert","year":"1979","journal-title":"Deutsche medizinische Wochenschrift (1946)"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V72.2.413.413","article-title":"Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive \"Angioimmunoblastic lymphadenopathy with dysproteinemia-type\" features","volume":"72","author":"Kaneko","year":"1988","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V72.3.1000.bloodjournal7231000","article-title":"Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma","volume":"72","author":"Tobinai","year":"1988","journal-title":"Blood"},{"key":"B19","article-title":"A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the international lymphoma study group","author":"Harris","year":"1995","journal-title":"Important Adv Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express Cd10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"Tet2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708","article-title":"Tet2 and Dnmt3a mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748","article-title":"Idh2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2872","article-title":"Somatic rhoa mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by who subtype in the united states, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010387%JBlood","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.06.012","article-title":"Up-front therapy with chop plus etoposide in Brazilian nodal ptcl patients: increased toxicity and no survival benefit compared to chop regimen-results of a real-life study from a middle-income country","volume":"22","author":"Lage","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br J haematology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000261","article-title":"The curious origins of angioimmunoblastic T-cell lymphoma","volume":"23","author":"Cort\u00e9s","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.11.1553","article-title":"Cxc chemokine receptor 5 expression defines follicular homing T cells with b cell helper function","volume":"192","author":"Schaerli","year":"2000","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02029-4","article-title":"Nonpolarized memory T cells","volume":"22","author":"Kim","year":"2001","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of Cxcl13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (Aitl): a new diagnostic marker providing evidence that aitl derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of Cxcl13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper T cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.017","article-title":"Icos coreceptor signaling inactivates the transcription factor Foxo1 to promote tfh cell differentiation","volume":"42","author":"Stone","year":"2015","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T Follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.06.009","article-title":"Helping the helpers","volume":"31","author":"Ma","year":"2009","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1411-z","article-title":"Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis","volume":"98","author":"Nagoshi","year":"2013","journal-title":"Int J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.7.927","article-title":"Survival and clonal expansion of mutating \"Forbidden\" (Immunoglobulin receptor-deficient) Epstein-Barr virus-infected b cells in angioimmunoblastic T cell lymphoma","volume":"194","author":"Br\u00e4uninger","year":"2001","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182785610","article-title":"Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-sternberg cells of b-cell lineage: both ebv-positive and ebv-negative variants exist","volume":"37","author":"Nicolae","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pathol.2019.09.012","article-title":"Approach to nodal-based T-cell lymphomas","volume":"52","author":"de Leval","year":"2020","journal-title":"Pathology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2012.02858.x","article-title":"Clinicopathological analysis of a composite lymphoma containing both T- and b-cell lymphomas","volume":"62","author":"Suefuji","year":"2012","journal-title":"Pathol Int"},{"key":"B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41389-020-00259-x","article-title":"New preclinical models for angioimmunoblastic T-cell lymphoma: filling the gap","volume":"9","author":"Mhaidly","year":"2020","journal-title":"Oncogenesis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.21.020604.150721","article-title":"Rho gtpases: biochemistry and biology","volume":"21","author":"Jaffe","year":"2005","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature01148","article-title":"Rho gtpases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"Rhoa G17v induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in rhoa gtpase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-220013","article-title":"Tet-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in ptcl, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients","volume":"35","author":"de P\u00e1dua Covas Lage","year":"2022","journal-title":"Cancer Biomarkers section A Dis Markers"},{"key":"B52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13148-022-01395-4","article-title":"Tumor mutation burden involving epigenetic regulatory genes and the rhoa gtpase predicts overall survival in nodal mature T-cell lymphomas","volume":"14","author":"de P\u00e1dua Covas Lage","year":"2022","journal-title":"Clin Epigenet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1172\/jci92026","article-title":"Mutations in 5-methylcytosine oxidase Tet2 and rhoa cooperatively disrupt T cell homeostasis","volume":"127","author":"Zang","year":"2017","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of rhoa-Vav1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22202","article-title":"Recurrent rhoa mutations in pediatric burkitt lymphoma treated according to the nhl-bfm protocols","volume":"53","author":"Rohde","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2984","article-title":"Recurrent gain-of-Function mutations of rhoa in diffuse-type gastric carcinoma","volume":"46","author":"Kakiuchi","year":"2014","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood-2015-06-644948","article-title":"Variegated rhoa mutations in adult T-cell Leukemia\/Lymphoma","volume":"127","author":"Nagata","year":"2016","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11899-011-0108-8","article-title":"Role of Tet2 mutations in myeloproliferative neoplasms","volume":"7","author":"Pronier","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of Tet1, Tet2, and Tet3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent Tet2 mutations in peripheral T-cell lymphomas correlate with tfh-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by mll partner Tet1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Sci (New York NY)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature09303","article-title":"Role of tet proteins in 5mc to 5hmc conversion, Es-cell self-renewal and inner cell mass specification","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/bcj.2014.83","article-title":"Reduced Tet2 function leads to T-cell lymphoma with follicular helper T-Cell-Like features in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Blood Cancer J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and nk-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644591","article-title":"Idh2r172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated Idh1 and Idh2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic Idh1 and Idh2 mutations result in a hypermethylation phenotype, disrupt Tet2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"Idh mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to tcr signaling in angioimmunoblastic and other follicular helper T-Cell-Derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-Type-Specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617929114","article-title":"The Idh2 R172k mutation associated with angioimmunoblastic T-cell lymphoma produces 2hg in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1806413","article-title":"High-risk clonal hematopoiesis as the origin of aitl and Npm1-mutated aml","volume":"379","author":"Tiacci","year":"2018","journal-title":"New Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.181","article-title":"Peripheral T-cell and nk-cell lymphomas in the who classification: pearls and pitfalls","author":"Jaffe","year":"2013","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.12","article-title":"Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers","volume":"22","author":"Rodriguez-Justo","year":"2009","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-cell lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00428-004-1114-1","article-title":"In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. a molecular single-cell and immunohistochemical study","volume":"446","author":"Willenbrock","year":"2005","journal-title":"Virchows Archiv an Int J Pathol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2015.11.002","article-title":"A difficult case of angioimmunoblastic T-cell lymphoma to diagnose","volume":"38","author":"Sachsida-Colombo","year":"2016","journal-title":"Rev Bras hematologia e hemoterapia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d'etude des lymphomes de l'adulte (Gela) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hon.2080","article-title":"Peripheral blood Scd3\u207b Cd4\u207a T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma","volume":"32","author":"Singh","year":"2014","journal-title":"Hematological Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.113","article-title":"Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant Cd3(-\/Dim)Cd4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic","volume":"29","author":"Alikhan","year":"2016","journal-title":"Modern Pathol an Off J United States Can Acad Pathology Inc"},{"key":"B83","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1309\/28yp-0del-gkej-grxg","article-title":"Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: emphasis on phenotypic aberrancies for early diagnosis","volume":"126","author":"Merchant","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (Pd-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (Sap and pd-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2011.03.003","article-title":"Follicular helper T cells: implications in neoplastic hematopathology","volume":"28","author":"Gaulard","year":"2011","journal-title":"Semin Diagn Pathol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3180339f18","article-title":"Epstein-Barr Virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features","volume":"31","author":"Balagu\u00e9","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.3797","article-title":"Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation","volume":"31","author":"Huppmann","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328186ffbf","article-title":"Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications","volume":"14","author":"Dunleavy","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of b-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br J Haematol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1365-2141.2008.07534.x","article-title":"Angiogenic mediators of the angiopoietin system are highly expressed by Cd10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma","volume":"144","author":"Konstantinou","year":"2009","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700145","article-title":"Vascular endothelial growth factor-a is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression","volume":"84","author":"Zhao","year":"2004","journal-title":"Lab investigation; J Tech Methods Pathol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04335.x","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"121","author":"Dogan","year":"2003","journal-title":"Br J Haematol"},{"key":"B95","first-page":"899","article-title":"Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies","volume":"6","author":"Alizadeh","year":"2008","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel T(5;9)(Q33;Q22) fuses itk to syk in unspecified peripheral T-cell lymphoma","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07042.x","article-title":"Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma","volume":"141","author":"Nelson","year":"2008","journal-title":"Br J Haematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2006.060016","article-title":"The frequency of b- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated b-cell proliferations","volume":"8","author":"Tan","year":"2006","journal-title":"J Mol Diagn JMD"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/life12030410","article-title":"Genetic landscape of peripheral T-cell lymphoma","volume":"12","author":"Hathuc","year":"2022","journal-title":"Life (Basel Switzerland)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14846","article-title":"Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.357","article-title":"Recurrent activating mutations of Cd28 in peripheral T-cell lymphomas","volume":"30","author":"Rohr","year":"2016","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1459610","article-title":"Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study","volume":"59","author":"Hong","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03731-w","article-title":"Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma","volume":"98","author":"de P\u00e1dua Covas Lage","year":"2019","journal-title":"Ann Hematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral b cells with rituximab in addition to chop in angioimmunoblastic T-cell lymphoma","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"A Clinicobiological Study Gela. Haematologica"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2742","article-title":"Ebv status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma","volume":"9","author":"Eladl","year":"2020","journal-title":"Cancer Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5248","article-title":"Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China","volume":"12","author":"Wei","year":"2022","journal-title":"Cancer Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.1038\/s41598-018-31212-z","article-title":"B2 microglobulin is a novel prognostic marker of angioimmunoblastic T-cell lymphoma","volume":"8","author":"Shang","year":"2018","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00511","article-title":"Practical treatment approach for angioimmunoblastic T-cell lymphoma","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J Oncol Pract"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060456","article-title":"Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma","volume":"28","author":"Mohammed Saleh","year":"2021","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109067633","article-title":"Singh AK. p-glycoprotein expression in drug-resistant chronic lymphoproliferative disorder","volume":"5","author":"Majumdar","year":"1991","journal-title":"Leukemia Lymphoma"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(94)90025-6","article-title":"Clinical relevance of p-glycoprotein expression in haematological malignancies","volume":"18","author":"Nooter","year":"1994","journal-title":"Leukemia Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.858154","article-title":"The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma","volume":"55","author":"Kansara","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single north American institution by the who classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell lymphomas, version 2.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Cancer Network JNCCN"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and nk-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1h) and chop chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a gitil (Gruppo italiano terapie innovative nei linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018254","article-title":"Multicenter phase 2 study of oral azacitidine (Cc-486) plus chop as initial treatment for peripheral T-cell lymphoma","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815","article-title":"Romidepsin plus chop versus chop in patients with previously untreated peripheral T-cell lymphoma: results of the ro-chop phase iii study (Conducted by lysa)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront vip-Reinforced-Abvd (Vip-rabvd) is not superior to Chop\/21 in newly diagnosed peripheral T cell lymphoma. results of the randomized phase iii trial goelams-Ltp95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (Pegs) in peripheral T-cell non-Hodgkin lymphoma: southwest oncology group study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and asct on survival among patients aged <65 years with stage ii to iv ptcl: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2924","article-title":"Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: a systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematological Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S189825","article-title":"Comparison of chop vs chope for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern cooperative oncology group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with chop in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.008","article-title":"Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis","volume":"176","author":"Meeuwes","year":"2022","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for Cd30-positive peripheral T-cell lymphoma (Echelon-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet (London England)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of ptcl-nos and aitl: current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br J Haematol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with ptcl: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with ptcl: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00023-x","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from lysa centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a Large us multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: nlg-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from complete, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1434","article-title":"Current treatment patterns and the role of upfront autologous stem cell transplantation in patients with peripheral T-cell lymphoma: a Korean nationwide, multicenter prospective registry study (Cisl 1404)","volume":"55","author":"Cho","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008825","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-nhl","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the gel-tamo experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.008","article-title":"High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (Ptcl): analysis of prognostic factors","volume":"17","author":"Nademanee","year":"2011","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the Relapsed\/Refractory setting: a systematic Review\/Meta-analysis","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.12.050","article-title":"Graft-Versus-Lymphoma effect in relapsed peripheral T-cell non-hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.1366","article-title":"Graft-Versus-Lymphoma effect for aggressive T-cell lymphomas in adults: a study by the soci\u00e9t\u00e9 francaise de greffe de mo\u00eblle et de th\u00e9rapie cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in Relapsed\/Refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-Versus-Lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in Relapsed\/Refractory ptcl (Cosmos): an open-label phase I\/Ii trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221143025","article-title":"Current state of car-T therapy for T-cell malignancies","volume":"13","author":"Luo","year":"2022","journal-title":"Ther Adv Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1177590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T05:52:34Z","timestamp":1682488354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1177590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":153,"alternative-id":["10.3389\/fonc.2023.1177590"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1177590","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"article-number":"1177590"}}